MTHFR and Stroke: Hence, patients without a history of stroke/CVD who benefited from the treatment could be reasonably viewed as those with a likely lower baseline tHcy and prevalence of MTHFR 677C>T wild-type subjects, whereas those with a history of stroke/CVD who did not benefit could be reasonably viewed as those with a likely higher baseline tHcy and prevalence of variant allele carriers.